Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) is a medical device company focused on device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine. This news page aggregates company-issued updates and market-moving announcements related to ClearPoint Neuro’s neurosurgical navigation systems, laser therapy platforms, intracranial fluid management technologies, and central nervous system drug delivery services.
Readers can follow earnings and financial updates, such as preliminary unaudited revenue results and quarterly reports furnished via Form 8-K, which outline trends in biologics and drug delivery revenue, neurosurgery navigation and therapy revenue, and capital equipment and software sales. News items also cover strategic transactions, including the completed acquisition of IRRAS Holdings, Inc., which adds the IRRAflow active fluid-exchange system and expands ClearPoint Neuro’s presence in neurocritical care and intracranial bleeding management.
ClearPoint Neuro’s news flow frequently highlights regulatory milestones like FDA 510(k) clearances, including expanded MRI compatibility for the ClearPoint Prism Neuro Laser Therapy System, and international regulatory approvals that extend product use to additional countries. The company also reports on clinical and scientific developments, such as Phase I–II study results in glioblastoma and grade 4 astrocytoma using ClearPoint Prism, as well as the development and demonstration of its proprietary Robotic Neuro-Navigation System.
Investors and observers can also track partnership and conference activity, including updates on more than 60 active biopharma partners, participation in global healthcare conferences, and progress at ClearPoint Advanced Laboratories. Bookmark this page to review historical and ongoing CLPT news related to neurosurgical devices, therapy delivery platforms, and the company’s role in enabling cell and gene therapy programs.
ClearPoint Neuro (Nasdaq: CLPT) has successfully closed a public stock offering, selling 2,127,660 shares, including 1,850,140 at $23.50 each and 277,520 following underwriters' options at $22.09. The net proceeds are approximately $46.8 million, which will support product development, R&D activities, and general corporate purposes. CEO Joe Burnett highlighted the strategic use of this capital to enhance the company’s capabilities in neuro-based therapies. B. Riley Securities managed the offering, with shares sold under an effective SEC registration statement.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) will release its financial results for Q4 and the full year 2020 on March 4, 2021, after market close. Investors can join a live call at 4:30 p.m. ET to discuss the results. ClearPoint specializes in neurosurgery navigation and drug delivery systems, currently having FDA clearance for its products, with installations across over 60 sites. The company is engaged with multiple biologics firms, supporting various stages of clinical trials. Forward-looking statements highlight potential impacts, including COVID-19, on future revenues and market acceptance.
ClearPoint Neuro (Nasdaq: CLPT) announced the pricing of a public offering of 1,850,140 shares of common stock at $23.50 per share, with an option for underwriters to purchase an additional 277,520 shares. The offering is set to close on February 23, 2021. Proceeds will fund product development and research, as well as general corporate purposes. B. Riley Securities is leading the offering, following SEC approval on January 29, 2021.
ClearPoint Neuro (Nasdaq: CLPT) has announced a proposed underwritten public offering of its common stock, with all shares being offered by the Company. This offering includes a 30-day option for underwriters to purchase additional shares, totaling up to 15% of the offering size. The offering is subject to market conditions, and there's no guarantee regarding its completion or terms. B. Riley Securities is the book-running manager, while Lake Street Capital Markets acts as the co-manager. The SEC has declared effective a shelf registration statement related to the offering.
ClearPoint Neuro (CLPT) announced a worldwide license and research agreement with Philips to develop the ‘Maestro™’ Brain Model, set for launch in 2022. This collaboration aims to enhance various applications in drug delivery, deep brain stimulation, laser ablation, and biopsies, enabling precise treatment paths and safer procedures. Philips' Brain Model technology, developed over 10 years, offers accurate assessments backed by extensive research. ClearPoint’s products are FDA cleared and used in over 60 clinical sites across the U.S., Canada, and Europe, supporting a diverse range of neurological therapies.
ClearPoint Neuro has announced a partnership with Blackrock Microsystems to develop innovative products in the neurosurgery market. This collaboration is set to tap into a combined addressable market exceeding $100 million. The first product, the Microelectric Recording (MER) platform, is expected to launch in 2023, followed by advanced biopsy needles and other neural electrodes. This strategic alliance combines ClearPoint's navigation expertise and Blackrock's precision electrode technology, aiming to enhance patient outcomes in neurosurgery.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of R. John Fletcher as Chairman of the Board, succeeding Kimble L. Jenkins, who retired to focus on his CEO role at OrthoSouth. Joe Burnett, CEO of ClearPoint, praised Jenkins for his contributions in growing the company. Fletcher, recognized for his leadership during Spectranetics' acquisition by Philips for $2.2 billion, aims to guide ClearPoint in its next growth phase. The company continues to advance its neurosurgery solutions, including FDA-cleared products for complex neurological disorders.
ClearPoint Neuro (Nasdaq: CLPT) announced the appointment of Ernesto Salegio, PhD, as Vice President, Segment Leader of Translational and Pre-Clinical Research, starting March 1, 2021. Dr. Salegio has over 19 years of experience in translational neuroscience, specializing in gene therapy delivery. He will enhance ClearPoint’s Biologics and Drug Delivery team, established in 2020, aimed at supporting pharmaceutical partners with pre-clinical services. ClearPoint aims to provide comprehensive medical device solutions for gene and stem cell therapies to improve patient care.
ClearPoint Neuro (Nasdaq: CLPT) has successfully implemented its Version 2.0 software along with the ClearPoint Navigation System at Rigshospitalet, Copenhagen, marking the first usage in Europe. This procedure utilized live MRI guidance for laser catheter navigation, showcasing the system's enhanced precision. Dr. Rune Rasmussen emphasized its superior accuracy compared to traditional methods. ClearPoint aims to expand its presence in Europe, attracting more partners for clinical trials and increasing its service reach across the EMEA region.
ClearPoint Neuro (CLPT) reported preliminary unaudited revenue of approximately $3.7 million for Q4 2020, marking a 14% increase year-over-year, while full-year 2020 revenue is estimated at $12.8 million, also a 14% growth. The company supported 175 cases in Q4 amid ongoing COVID-19 disruptions. Cash used in operations was approximately $2.4 million in Q4 and $7.9 million for the full year, with cash and cash equivalents at $20.1 million as of December 31, 2020.
CEO Joe Burnett noted challenges posed by COVID-19, anticipating ongoing pressures on elective procedures into the first half of 2021.